PTC Therapeutics Offers Competitive Stock Options to New Employees

PTC Therapeutics' Inducement Grants Explained

On March 10, 2026, PTC Therapeutics, Inc., a biopharmaceutical company specializing in rare disorders, announced the approval of significant stock options and restricted stock units (RSUs) for new employees. This initiative follows the Nasdaq Listing Rule 5635(c)(4), designed to attract talent in the competitive biotech sector.

The company's Compensation Committee authorized non-statutory stock options allowing the purchase of 14,550 shares and 17,515 RSUs. These awards are critical components of the new hires' employment packages, granted to incentivize their acceptance of job offers. Each RSU is valued at the company's common stock price on that day, which was $68.56.

Details of the Stock Options and RSUs

The stock options come with a 10-year term and are structured to vest over a four-year period. For the first year, 25% of the shares will vest on the first anniversary of each employee's start date, with an additional 6.25% vesting at the end of each subsequent three-month period until all are vested. Importantly, vesting is contingent on the ongoing employment of the individuals at PTC Therapeutics.

For the RSUs, the vesting schedule is identical in duration, with 25% vesting each year on the anniversary of the hire date. This approach aims to provide new employees with a sense of financial security and commitment to the company's vision from the outset.

PTC Therapeutics: Company Overview

PTC Therapeutics is at the forefront of biopharmaceutical innovation, dedicated to developing medicines for individuals with rare disorders. The company's mission focuses on providing transformative therapies that meet unmet medical needs. By leveraging its scientific expertise and a robust commercial infrastructure, PTC aims to enhance value for both patients and stakeholders.

As PTC Therapeutics continues to grow, it maintains its commitment to creating an environment where the best minds can work on pioneering treatments. The recent inducement grants serve not only as a tool for recruitment but also reflect the company's dedication to fostering a supportive workplace aligned with its strategic goals.

Looking Ahead

This stock option initiative is a strategic move that signals PTC Therapeutics' commitment to attracting and retaining top-tier talent in the biotechnology field. As the industry evolves, firms like PTC must adapt their employment strategies to remain competitive, particularly in attracting skilled professionals who are essential for innovation in the healthcare ecosystem.

For more information about PTC Therapeutics and its work, interested parties can visit www.ptcbio.com or follow the company on social media platforms like LinkedIn, Twitter (X), Instagram, and Facebook. Investors and media inquiries can contact Ellen Cavaleri at +1 (615) 618-8228 or Jeanine Clemente at +1 (908) 912-9406 for further details regarding this announcement and other company initiatives.